胶质母细胞瘤中的生物钟
本文综述了昼夜节律钟在胶质母细胞瘤(GBM)生物学中的关键作用及治疗策略。核心钟蛋白BMAL1和CLOCK在GBM中高表达并与不良预后相关,促进GBM干细胞维持和促肿瘤微环境形成,提示靶向核心钟蛋白可能增强GBM治疗。
要点
- BMAL1和CLOCK在胶质母细胞瘤中高表达并与患者不良预后相关。
- BMAL1和CLOCK促进胶质母细胞瘤干细胞维持及促肿瘤微环境形成。
- 靶向核心钟蛋白可能增强胶质母细胞瘤治疗,生物钟策略或可用于临床。
核心结论
- 昼夜节律钟在胶质母细胞瘤生物学中发挥关键作用,靶向核心钟蛋白可能增强胶质母细胞瘤治疗。
研究设计与样本
- 综述,总结昼夜节律钟在胶质母细胞瘤生物学中的作用及利用生物钟进行临床治疗的策略。
主要发现
- 胶质母细胞瘤占所有诊断肿瘤的14.2%、所有恶性肿瘤的50.1%,中位生存时间约8个月,无论是否接受治疗均无明显改善(Ostrom QT等,CBTRUS统计报告,2015-2019年美国诊断的原发性脑及其他中枢神经系统肿瘤,Neuro Oncol 2022;24(Suppl 5):v1-v95)。
- 昼夜节律控制转录的正调控因子BMAL1和CLOCK在胶质母细胞瘤中亦高表达,并与患者不良预后相关。
- BMAL1和CLOCK促进胶质母细胞瘤干细胞(GSC)维持及促肿瘤微环境(TME)形成。
关键数值与推荐
- 胶质母细胞瘤占所有诊断肿瘤的14.2%。
- 胶质母细胞瘤占所有恶性肿瘤的50.1%。
- 胶质母细胞瘤中位生存时间约8个月,无论是否接受治疗均无明显改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma (GBM) is the most prevalent malignant primary brain tumor, accounting for 14.2% of all diagnosed tumors and 50.1% of all malignant tumors, and the median survival time is approximately 8 months irrespective of whether a patient receives treatment without significant improvement despite expansive research (Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neurooncology. 2022; 24(suppl 5):v1-v95.). Recently, important roles for the circadian clock in GBM tumorigenesis have been reported. Positive regulators of circadian-controlled transcription, brain and muscle ARNT-like 1 (BMAL1), and circadian locomotor output cycles kaput (CLOCK), are highly expressed also in GBM and correlated with poor patient prognosis. BMAL1 and CLOCK promote the maintenance of GBM stem cells (GSCs) and the establishment of a pro-tumorigenic tumor microenvironment (TME), suggesting that targeting the core clock proteins may augment GBM treatment. Here, we review findings that highlight the critical role the circadian clock plays in GBM biology and the strategies by which the circadian clock can be leveraged for GBM treatment in the clinic moving forward.
引用
- Chan P, Rich JN, Kay SA, et al. Watching the clock in glioblastoma. Neuro Oncol. 2023. PMID: 37326042. doi:10.1093/neuonc/noad107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。